• Something wrong with this record ?

Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training

M. Srp, V. Capek, O. Gal, EK. Havrdova, R. Jech, R. Korteova, K. Novotna, E. Ruzicka, H. Ruzickova, B. Srpova, M. Hoskovcova

. 2021 ; 55 (-) : 103187. [pub] 20210805

Language English Country Netherlands

Document type Journal Article

BACKGROUND: The efficacy of expiratory muscle strength training (EMST) in patients with multiple sclerosis (MS) is controversial. The current study's primary objective was to test the effects of a progressive and intensive 12 week home based EMST program on expiratory muscle strength and voluntary cough strength. The secondary objective was to determine the retention of EMST benefits. METHODS: Thirty-five severely disabled MS patients (relapsing-remitting MS, n = 15; primary progressive MS, n = 5; secondary progressive MS, n = 15) with Expanded Disability Status Scale (EDSS) 5.0 - 7.0 were included in the study. Within 36 weeks, patients completed 12 weeks of a non-training period, 12 weeks of EMST and 12 weeks of a detraining period. Maximal expiratory pressure (PEmax) and voluntary peak cough flow (vPCF) were assessed 4 times: at week 0 (baseline), week 12 (pre-training), week 24 (post-training), and week 36 (post-detraining). MS patients included in the study were compared to age- and sex-matched healthy subjects. In the healthy controls, the PEmax and vPCF were assessed once to obtain normative data. RESULTS: Twenty-six patients completed the training period (mean age 52.7 ± 10.2, EDSS 5.9 ± 0.6) and were compared to 26 sex- and age-matched healthy subjects (mean age 53.5 ± 5.8). Patients with MS had a lower PEmax (p = 0.002) and vPCF (p = 0.022) at baseline than the healthy control group. In training period, the PEmax and vPCF increased (p = 0.0000; effect size: d = 0.94 and p = 0.0036; d = 0.57 respectively) in comparison with the non-training period (p = 0.0692; d = -0.36 and p = 0.5810; d = 0.11 respectively). Following the 12 weeks detraining period, the PEmax and vPCF declined but remained 16.7% and 5.5% respectively above the pre-training values. No differences were observed in the PEmax and vPCF between the MS group at the post-training and post-detraining timepoint and the healthy control group normative values. CONCLUSIONS: EMST improves expiratory muscle strength and voluntary cough strength in severely disabled MS patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003623
003      
CZ-PrNML
005      
20240903113231.0
007      
ta
008      
220113e20210805ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.msard.2021.103187 $2 doi
035    __
$a (PubMed)34388534
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Srp, Martin $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic. Electronic address: martin.srp@vfn.cz
245    10
$a Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training / $c M. Srp, V. Capek, O. Gal, EK. Havrdova, R. Jech, R. Korteova, K. Novotna, E. Ruzicka, H. Ruzickova, B. Srpova, M. Hoskovcova
520    9_
$a BACKGROUND: The efficacy of expiratory muscle strength training (EMST) in patients with multiple sclerosis (MS) is controversial. The current study's primary objective was to test the effects of a progressive and intensive 12 week home based EMST program on expiratory muscle strength and voluntary cough strength. The secondary objective was to determine the retention of EMST benefits. METHODS: Thirty-five severely disabled MS patients (relapsing-remitting MS, n = 15; primary progressive MS, n = 5; secondary progressive MS, n = 15) with Expanded Disability Status Scale (EDSS) 5.0 - 7.0 were included in the study. Within 36 weeks, patients completed 12 weeks of a non-training period, 12 weeks of EMST and 12 weeks of a detraining period. Maximal expiratory pressure (PEmax) and voluntary peak cough flow (vPCF) were assessed 4 times: at week 0 (baseline), week 12 (pre-training), week 24 (post-training), and week 36 (post-detraining). MS patients included in the study were compared to age- and sex-matched healthy subjects. In the healthy controls, the PEmax and vPCF were assessed once to obtain normative data. RESULTS: Twenty-six patients completed the training period (mean age 52.7 ± 10.2, EDSS 5.9 ± 0.6) and were compared to 26 sex- and age-matched healthy subjects (mean age 53.5 ± 5.8). Patients with MS had a lower PEmax (p = 0.002) and vPCF (p = 0.022) at baseline than the healthy control group. In training period, the PEmax and vPCF increased (p = 0.0000; effect size: d = 0.94 and p = 0.0036; d = 0.57 respectively) in comparison with the non-training period (p = 0.0692; d = -0.36 and p = 0.5810; d = 0.11 respectively). Following the 12 weeks detraining period, the PEmax and vPCF declined but remained 16.7% and 5.5% respectively above the pre-training values. No differences were observed in the PEmax and vPCF between the MS group at the post-training and post-detraining timepoint and the healthy control group normative values. CONCLUSIONS: EMST improves expiratory muscle strength and voluntary cough strength in severely disabled MS patients.
650    _2
$a dospělí $7 D000328
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a roztroušená skleróza $7 D009103
650    _2
$a svalová síla $7 D053580
650    12
$a odporový trénink $7 D055070
650    _2
$a dýchací svaly $7 D012132
655    _2
$a časopisecké články $7 D016428
700    1_
$a Capek, Vaclav $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
700    1_
$a Gal, Ota $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
700    1_
$a Havrdova, Eva Kubala $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
700    1_
$a Jech, Robert $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
700    1_
$a Korteova, Rebeka $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
700    1_
$a Novotna, Klara $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
700    1_
$a Ruzicka, Evzen $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
700    1_
$a Ruzickova, Hana $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
700    1_
$a Srpová, Barbora $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic $7 xx0321726
700    1_
$a Hoskovcova, Martina $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
773    0_
$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 55 (20210805), s. 103187
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34388534 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20240903113228 $b ABA008
999    __
$a ok $b bmc $g 1751169 $s 1154772
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 55 $c - $d 103187 $e 20210805 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...